Back To TOP

Find Patient Assistance Patient Assistance Programs

We offer several options to help cover the cost of Tarceva® (erlotinib) tablets for your patients who are uninsured, have been denied coverage by their health plans, have concerns about co-pays or are worried about out-of-pocket expenses.

 


 

 

Genentech BioOncology Co-pay Card

Genentech offers the Genentech BioOncology Co-pay Card to help qualified patients with the out-of-pocket costs associated with their Tarceva prescription.

 

 

 

 

 

Referrals to Co-pay Assistance Foundations

If privately or publicly insured patients have difficulty paying for their Tarceva co-pay, co-insurance or other expenses, Tarceva Access Solutions can refer them to a co-pay assistance foundation* supporting their disease state.

 

 

 

 

 

 

 

Genentech® Access to Care Foundation (GATCF)

GATCF was established to help patients with unmet medical needs who are uninsured or rendered uninsured by payer denial and who meet specific financial and medical criteria to receive Tarceva free of charge. Learn more

 

* Genentech and Astellas Pharmaceuticals do not influence or control the operations of these co-pay assistance foundations, but Tarceva Access Solutions can assist patients in navigating the process of seeking co-pay assistance by making an appropriate referral based on a patient’s diagnosis and by assisting with the application process. We cannot guarantee co-pay assistance once a patient has been referred by Tarceva Access Solutions. The foundations to which we refer patients each have their own criteria for patient eligibility, including financial eligibility.

 

 

Learn More About
Tarceva
  • LEARN about treatment with Tarceva
  • NOW APPROVED as first-line therapy for metastatic non–small cell lung cancer (NSCLC) patients with exon 19 and 21 epidermal growth factor receptor (EGFR) mutations.
  • LEARN HOW the Genentech BioOncology Co-pay Card can help with the out-of-pocket costs for Tarceva
  • Download: new forms for enrollment in GATCF
  • Form Statement of Medical Necessity
  • Form Patient Authorization and Notice of Release of Information

Tarceva Indications and Important Safety Information

INDICATIONS

Advanced Non-Small Cell Lung Cancer (NSCLC)
Tarceva is indicated for:

  • The first-line treatment of patients with metastatic NSCLC whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.
  • The maintenance treatment of patients with locally advanced or metastatic NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.
  • The treatment of patients with locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen.

Limitations of use:

  • Tarceva is not recommended for use in combination with platinum-based chemotherapy.
  • Safety and efficacy of Tarceva have not been evaluated as first-line treatment in patients with metastatic NSCLC whose tumors have EGFR mutations other than exon 19 deletions or exon 21 (L858R) substitution.

Advanced Pancreatic Cancer

  • Tarceva in combination with gemcitabine is indicated for the first-line treatment of patients with locally advanced, unresectable, or metastatic pancreatic cancer

Important safety information

    • CONTRAINDICATIONS: None
    • WARNINGS AND PRECAUTIONS:

- Cases of serious interstitial lung disease (ILD), including fatal cases, have been reported.

- Hepatic failure, hepatorenal syndrome, and severe acute renal failure (all including fatal cases) and renal insufficiency have been reported.

- Gastrointestinal perforation (including fatal cases) has been reported.

- Bullous, blistering and exfoliative skin conditions, including cases suggestive of Stevens-Johnson syndrome/toxic epidermal necrolysis, which in some cases were fatal, have been reported.

- In the pooled incidences in the 3 monotherapy lung studies and the pancreatic carcinoma trial, serious adverse reactions, including fatal cases, such as myocardial infarction/ischemia, cerebrovascular accident, and microangiopathic hemolytic anemia with thrombocytopenia were reported.

- Corneal perforation or ulceration have been reported.

- Severe and fatal hemorrhage associated with INR elevations can occur when Tarceva and warfarin are used concurrently.

- Embryo-fetal toxicity. Tarceva is pregnancy category D. Women should be advised to avoid pregnancy or breastfeeding.

  • MOST COMMON ADVERSE REACTIONS:

- Metastatic NSCLC – First-Line Treatment of Patients With EGFR Mutations:

- Diarrhea, asthenia, rash, cough, dyspnea, and decreased appetite.

- Advanced NSCLC – Maintenance and Second/Third-Line Treatment:

- Rash and diarrhea.

- Advanced Pancreatic Cancer – Tarceva Administered Concurrently with Gemcitabine:

- Fatigue, rash, nausea, anorexia, and diarrhea.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.

For additional Important Safety Information, please see accompanying full prescribing information.

Tarceva® and its logo are trademarks of OSI Pharmaceuticals, LLC, an affiliate of Astellas Pharma US, Inc.

The Access Solutions logo is a registered trademark of Genentech, Inc.